JP2021513843A5 - - Google Patents
Info
- Publication number
- JP2021513843A5 JP2021513843A5 JP2020543282A JP2020543282A JP2021513843A5 JP 2021513843 A5 JP2021513843 A5 JP 2021513843A5 JP 2020543282 A JP2020543282 A JP 2020543282A JP 2020543282 A JP2020543282 A JP 2020543282A JP 2021513843 A5 JP2021513843 A5 JP 2021513843A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- modified
- mutation
- adenovirus according
- modified adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023191972A JP2024020345A (ja) | 2018-02-16 | 2023-11-10 | 改変アデノウイルス |
| JP2025025180A JP2025081522A (ja) | 2018-02-16 | 2025-02-19 | 改変アデノウイルス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802539.5A GB201802539D0 (en) | 2018-02-16 | 2018-02-16 | Modified adenoviruses |
| GB1802539.5 | 2018-02-16 | ||
| PCT/GB2019/050380 WO2019158914A1 (en) | 2018-02-16 | 2019-02-13 | Modified adenoviruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191972A Division JP2024020345A (ja) | 2018-02-16 | 2023-11-10 | 改変アデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513843A JP2021513843A (ja) | 2021-06-03 |
| JP2021513843A5 true JP2021513843A5 (enExample) | 2023-06-01 |
| JP7862138B2 JP7862138B2 (ja) | 2026-05-19 |
Family
ID=61783770
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543282A Active JP7862138B2 (ja) | 2018-02-16 | 2019-02-13 | 改変アデノウイルス |
| JP2023191972A Pending JP2024020345A (ja) | 2018-02-16 | 2023-11-10 | 改変アデノウイルス |
| JP2025025180A Pending JP2025081522A (ja) | 2018-02-16 | 2025-02-19 | 改変アデノウイルス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191972A Pending JP2024020345A (ja) | 2018-02-16 | 2023-11-10 | 改変アデノウイルス |
| JP2025025180A Pending JP2025081522A (ja) | 2018-02-16 | 2025-02-19 | 改変アデノウイルス |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12318418B2 (enExample) |
| EP (1) | EP3737403B1 (enExample) |
| JP (3) | JP7862138B2 (enExample) |
| KR (1) | KR102687425B1 (enExample) |
| CN (2) | CN118834841A (enExample) |
| AU (1) | AU2019220607B2 (enExample) |
| CA (1) | CA3090859C (enExample) |
| DK (1) | DK3737403T5 (enExample) |
| ES (1) | ES2968387T3 (enExample) |
| FI (1) | FI3737403T3 (enExample) |
| GB (1) | GB201802539D0 (enExample) |
| IL (1) | IL276535B2 (enExample) |
| PL (1) | PL3737403T3 (enExample) |
| PT (1) | PT3737403T (enExample) |
| SG (1) | SG11202007470QA (enExample) |
| WO (1) | WO2019158914A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| GB201802539D0 (en) * | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| WO2021205364A1 (en) * | 2020-04-07 | 2021-10-14 | Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. | Engineered oncolytic adenovirus |
| CA3209730A1 (en) * | 2021-03-29 | 2022-10-06 | Alan Parker | Modified adenovirus |
| GB202214580D0 (en) | 2022-10-04 | 2022-11-16 | Univ College Cardiff Consultants Ltd | Adenoviral vector therapy |
| GB202314435D0 (en) | 2023-09-20 | 2023-11-01 | Univ College Cardiff Consultants Ltd | Modified adenovirus |
| CN121203037B (zh) * | 2025-09-26 | 2026-05-12 | 北京因诺惟康医药科技有限公司 | 基于整合素改造的特异性靶向心脏及肌肉的aav9优势突变体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1516055A4 (en) | 2002-01-24 | 2007-08-08 | Scripps Research Inst | FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS |
| CA2519680A1 (en) * | 2003-03-28 | 2004-11-18 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| GB0520068D0 (en) * | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| ES2367227T3 (es) * | 2007-03-14 | 2011-10-31 | Institut Catala D'oncologia | Adenovirus con mutaciones en el dominio de retención en el retículo endoplasmático de la proteína e3-19k y su utilización en el tratamiento del cáncer. |
| US20110104788A1 (en) * | 2008-02-07 | 2011-05-05 | Andrew Baker | Modulation of Adenoviral Tropism |
| AU2011306846B2 (en) * | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| EP3247807B1 (en) | 2015-01-20 | 2020-12-16 | Adcure Biotechnologies, LLC. | Detargeted adenovirus variants and related methods |
| GB201802539D0 (en) * | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
-
2018
- 2018-02-16 GB GBGB1802539.5A patent/GB201802539D0/en not_active Ceased
-
2019
- 2019-02-13 JP JP2020543282A patent/JP7862138B2/ja active Active
- 2019-02-13 FI FIEP19711157.8T patent/FI3737403T3/fi active
- 2019-02-13 CN CN202410794965.6A patent/CN118834841A/zh active Pending
- 2019-02-13 KR KR1020207026679A patent/KR102687425B1/ko active Active
- 2019-02-13 PT PT197111578T patent/PT3737403T/pt unknown
- 2019-02-13 PL PL19711157.8T patent/PL3737403T3/pl unknown
- 2019-02-13 ES ES19711157T patent/ES2968387T3/es active Active
- 2019-02-13 EP EP19711157.8A patent/EP3737403B1/en active Active
- 2019-02-13 US US16/970,003 patent/US12318418B2/en active Active
- 2019-02-13 CA CA3090859A patent/CA3090859C/en active Active
- 2019-02-13 SG SG11202007470QA patent/SG11202007470QA/en unknown
- 2019-02-13 CN CN201980026226.XA patent/CN112020368B/zh active Active
- 2019-02-13 IL IL276535A patent/IL276535B2/en unknown
- 2019-02-13 WO PCT/GB2019/050380 patent/WO2019158914A1/en not_active Ceased
- 2019-02-13 AU AU2019220607A patent/AU2019220607B2/en active Active
- 2019-02-13 DK DK19711157.8T patent/DK3737403T5/da active
-
2023
- 2023-11-10 JP JP2023191972A patent/JP2024020345A/ja active Pending
-
2025
- 2025-02-19 JP JP2025025180A patent/JP2025081522A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3737403T3 (fi) | Modifioituja adenoviruksia | |
| Kanerva et al. | Modified adenoviruses for cancer gene therapy | |
| JP2020517635A5 (enExample) | ||
| JP2020143128A5 (enExample) | ||
| ES2871907T3 (es) | Portadores de vacuna de adenovirus de chimpancé | |
| Lin et al. | TM4SF1: a new vascular therapeutic target in cancer | |
| CA2680659C (en) | Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment | |
| PT2293804E (pt) | Vírus herpes simplex (hsv) com tropismo modificado, suas utilizações e processo de preparação | |
| FI3768830T3 (fi) | Syöpäterapia | |
| RU2013118724A (ru) | Онколитические аденовирусные векторы и связанные с ними способы и применения | |
| Lu et al. | Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells | |
| CA2640528A1 (en) | Oncolytic adenoviruses for cancer treatment | |
| Iqbal et al. | Role of hepatitis C virus induced osteopontin in epithelial to mesenchymal transition, migration and invasion of hepatocytes | |
| Chen et al. | Aptamer modification improves the adenoviral transduction of malignant glioma cells | |
| Verheije et al. | Retargeting of viruses to generate oncolytic agents | |
| Yu et al. | Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors | |
| Garas et al. | Construction of a pIX-modified adenovirus vector able to effectively bind to nanoantibodies for targeting | |
| ES2963934T3 (es) | Inhibidores de Bcl 2 para uso en el tratamiento de un cáncer mediado por Bcl 2 que porta la mutación Gly101Val | |
| Behr et al. | Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds | |
| Gamble et al. | Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy | |
| Tanaka et al. | Cancer-targeting gene therapy using tropism-modified adenovirus | |
| Javier et al. | Mammary tumors induced by human adenovirus type 9: a role for the viral early region 4 gene | |
| Logunov et al. | Identification of HI-like loop in CELO adenovirus fiber for incorporation of receptor binding motifs | |
| Liu et al. | Genetically modified adenoviral vector with the protein transduction domain of Tat improves gene transfer to CAR-deficient cells | |
| Kanerva et al. | Gene therapy of gynaecological diseases |